Clinical trials: Body Weight Control
Obesity, Overweight
Efficacy and Safety of IQP-VV-102 in Weight Management
Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored
- Trial name
- NCT01681069
- Testing
- IQP-VV-102
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity, Weight Management
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
- Trial name
- NCT07073417
- Testing
- XW003 injection, semaglutide injection
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Overweight
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07215559
- Testing
- Macupatide, Eloralintide
- Where
- 42 sites in United States, Argentina and 2 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Adiposity
Study on the Performance of Symmcora® Mid-term Suture Versus Novosyn® Suture in Patients Undergoing Robotic Assisted Gastric Bypass Surgery
The study is designed as a prospective, mono-centric, randomized, patient blinded comparison of unidirectional barbed suture (Symmcora® mid term, UBS) vs. a conventional suture (Novosyn®, CS).
- Trial name
- BARGASTRO (NCT05433688)
- Testing
- Robotic assisted gastric bypass surgery
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Aesculap AG
Obesity, Overweight
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.
- Trial name
- NCT03479762
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 105 people
- Sponsor
- Novo Nordisk A/S
Obesity or Overweight, Diabetes Mellitus, Type 2
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 2 (NCT07784270)
- Testing
- Lenbelintide
- Where
- 230 sites in United States, Argentina and 14 more
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by…
- Trial name
- NCT07431086
- Testing
- Olatorepatide
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight and Obesity
Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and Obesity
Clinical trial, multicenter, double-blind, placebo-controlled, comparative of three parallel groups, randomized treatment to assess the efficacy and safety using a fixed dose combination of metformin hydrochloride with fluoxetine…
- Trial name
- Metfluo (NCT03051451)
- Testing
- combination metformin hydrochloride/ fluoxetine 500/20 mg, combination metformin hydrochloride/ fluoxetine 1000/20mg
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Obesity
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Trial name
- NCT07458269
- Testing
- Ribupatide
- Where
- 35 sites in United States
- Volunteers
- 264 people
- Sponsor
- Kailera
Obesity, Over-weight
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
- Conditions
- Obesity, Over-weight, Prader-Willi Syndrome
- Trial name
- NCT01818921
- Testing
- ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Zafgen, Inc.
Overweight, Obesity
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
- Trial name
- NCT06047548
- Testing
- Tirzepatide
- Where
- 20 sites in United States
- Volunteers
- 441 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite…
- Conditions
- Overweight, Obesity, Weight Management, Appetite Control
- Trial name
- NCT07895563
- Testing
- MN Nutra GeLiPthin-1™ Dietary Supplement
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- MNnutra
Overweight or Obesity
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.
- Trial name
- NCT07594093
- Testing
- REGN20934
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight (BMI > 25)
AIM-WEIGHT: AI-Guided Microbiome-Targeted Nutritional Intervention for Weight Loss
AIM-WEIGHT is a clinical study evaluating whether a fixed microbiome-targeted nutritional supplement can support weight loss in adults with overweight or obesity who do not have prediabetes or diabetes.
- Trial name
- AIM-WEIGHT (NCT07736547)
- Testing
- AI-Guided Microbiome-Targeted Nutritional Supplement, Lifestyle counselling
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Varol TUNALI
Overweight, Obesity
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous…
- Trial name
- NCT00673387
- Testing
- pramlintide acetate, metreleptin
- Where
- 36 sites in United States
- Volunteers
- 636 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Obesity
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese…
- Trial name
- NCT07223216
- Testing
- BMF-650
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Biomea Fusion Inc.
Overweight and Obesity, Healthy
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily [BID]) or placebo for 5 days beginning on Day 1.
- Trial name
- NCT06500429
- Testing
- NG101, Semaglutide Injectable Product
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Neurogastrx, Inc.
Overweight, Obesity
Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients
This is a randomized, double-blind, placebo-controlled, dose-finding, Phase 2a study designed to evaluate the safety and efficacy of KDS2010 in overweight or obese patients.
- Conditions
- Overweight, Obesity, Obese Patients
- Trial name
- NCT07009171
- Testing
- KDS2010
- Where
- 3 sites in South Korea
- Volunteers
- 75 people
- Sponsor
- NeuroBiogen Co., Ltd
Obesity, Microalbuminuria
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
Primary objective: To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.
- Conditions
- Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia
- Trial name
- RIALTO (NCT00458081)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Sanofi